(redirected from Lumizyme)


(al-gloo-ko-side-ase) ,


(trade name),


(trade name)


Therapeutic: replacement enzyme
Pregnancy Category: B


Myozyme: Replacement enzyme in infantile-onset Pompe disease (alpha glucosidase (GAA) deficiency).Lumizyme: Replacement enzyme in late-onset (non-infantile) Pompe disease in patients without evidence of cardiac hypertrophy.


Replaces alpha-glucosidase. Without this enzyme, glycogen accumulates in tissues including cardiac and skeletal muscles and hepatic tissues, leading to the development of cardiomyopathy, progressive muscle weakness, and impairment of respiratory function.

Therapeutic effects

Improved survival with delayed need for ventilatory support.
Improved lung function and exercise capacity.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 2.3–2.5 hr.

Time/action profile

IVunknownend of infusion2 wk


Contraindicated in: None known.
Use Cautiously in: Acute underlying illness (↑ risk of infusion reactions); Obstetric: Use only if clearly needed; Lactation: Lactation; Pediatric: Safety not established in children <1 mo or >3.5 yr (Myozyme) or <8 yr (Lumizyme).

Adverse Reactions/Side Effects


  • bradycardia (most frequent)
  • tachycardia (most frequent)


  • respiratory distress failure
  • cough (most frequent)
  • ↓ oxygen saturation (most frequent)
  • tachypnea

Ear, Eye, Nose, Throat

  • blurred vision
  • vertigo


  • constipation (most frequent)
  • diarrhea (most frequent)
  • reflux (most frequent)
  • vomiting (most frequent)


  • necrotizing skin lesions (life-threatening)
  • flushing (most frequent)
  • rash (most frequent)
  • dermatitis (most frequent)
  • urticaria (most frequent)


  • anemia (most frequent)
  • lymphadenopathy

Fluid and Electrolyte

  • edema


  • allergic reactions including anaphylaxis (life-threatening)
  • infusion reactions (life-threatening)
  • fever (most frequent)


Drug-Drug interaction

None noted.


Intravenous (Children 1 mo–3.5 yr) Myozyme—20 mg/kg every 2 wk.
Intravenous (Adults and Children ≥8 yr) Lumizyme—20 mg/kg every 2 wk.


Lyophilized powder for IV administration (requires reconstitution): 50 mg/vial

Nursing implications

Nursing assessment

  • Observe for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Keep epinephrine, an antihistamine, corticosteroids, and resuscitation equipment close by in case of anaphylactic reaction.
  • Monitor for infusion-related reactions (headache, fever, tachycardia, cough, cyanosis, rash, erythema, urticaria, hypotension. Most reactions are managed with antihistamines and/or corticosteroids prior to or during infusions, slowing rate of infusion, and/or early discontinuation if reaction is serious. Infusion reactions may occur any time during or up to 2 hr after infusion and are more likely with higher infusion rates.
  • Monitor cardiorespiratory status continuously during therapy. May cause acute cardiorespiratory failure requiring intubation and inotropic support.
  • Lab Test Considerations: Monitor liver enzymes prior to and periodically during therapy.

Potential Nursing Diagnoses

Ineffective tissue perfusion (Indications)


  • Lumizyme is available only through a restricted distribution program called the LUMIZYME ACE Program due to the potential risk of rapid disease progression in Pompe disease patients less than 8 yrs of age. Only prescribers and healthcare facilities enrolled in the program may prescribe, dispense or administer Lumizyme. Lumizyme may be administered only to patients who are enrolled in and meet all the conditions of the Lumizyme ACE Program. To enroll in the Lumizyme ACE Program call 1-800-745-4447.
  • Intravenous Administration
  • Intermittent Infusion: Determine number of vials required for the dose ordered. If number of vials includes a fraction, round up to next whole number. Allow vials to reach room temperature before reconstitution, approximately 30 min. Reconstitute by slowly injecting 10.3 mL of Sterile Water for Injection to inside wall of each vial. Avoid forceful impact of water on powder to avoid foaming. Tilt and roll each vial gently. Do not invert, swirl, or shake. Protect solution from light. Each vial contains 5 mg/mL with a total extractable dose of 50 mg/10 mL. Solution is clear and may occasionally contain white strands or translucent fibers; do not administer solutions that are discolored or contain particulate matter. Vials are for single use; discard remaining medication. Diluent: Dilute each vial in 100 mL of 0.9% NaCl immediately after reconstitution. Concentration: 0.5–4 mg/mL. Slowly withdraw reconstituted solution from each vial. Remove airspace from infusion bag to minimize particle formation due to sensitivity of medication to air. Add reconstituted solution slowly and directly into 0.9% NaCl solution, not into airspace in bag. Gently invert or massage to mix; do not shake. Use a 0.2 micrometer low-protein binding in-line filter for administration. Administer immediately. Solution may be stored in refrigerator for up to 24hr.
  • Rate: Administer over 4 hr. Using an infusion pump, administer initially at a rate of 1 mg/kg/hr. ↑ rate to 2 mg/kg/hr every 30 min, after tolerance to medication is established, until a maximum rate of 7 mg/kg/hr is reached. Monitor vital signs with each dose ↑. If stable, administer at 7 mg/kg/hr until infusion is completed. Slow or temporarily stop infusion if infusion reactions occur.

Patient/Family Teaching

  • Inform patient that a registry for patients with Pompe disease was established to evaluate long term treatments. Women of childbearing potential are also encouraged to register. For information, visit or call 1-800-745-4447.

Evaluation/Desired Outcomes

  • Improved survival with delayed need for ventilatory support in patients with Pompe disease.
  • Improved lung function and exercise capacity.
References in periodicals archive ?
While at Genzyme he played a central role in the development and approval of several therapies for rare diseases, including Fabrazyme, Aldurazyme, Myozyme and Lumizyme.
Although the drug was produced by the same company with exactly the same process as at the smaller scale, the FDA considered the larger-scale version to be a new product and even required that it adopt a different name; the two products are marketed as Myozyme and Lumizyme.
Food and Drug Administration today announced the approval of Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than 8 years of age.
Food and Drug Administration approval for a large-batch version of its Lumizyme drug for Pompe disease, a rare genetic disorder.
She has been receiving infusions since last month of Lumizyme every other week at Massachusetts General Hospital in Boston.
Genzyme currently produces Myozyme and Lumizyme at an adjacent plant in Geel, where it is increasing production capacity to 12,000 liters with the addition of a third bioreactor scheduled for approval by the end of this year.
Increases in both fourth-quarter and full-year revenue reflect, in part, sales of Lumizyme following FDA approval in May 2010.
4% compared to the same period of 2010 and were driven by continued expansion of Lumizyme [R] in the U.
Growth in the third quarter was driven by continued expansion of Lumizyme in the U.
NYSE: HSP), under which Hospira will perform fill/finish activities for several products in Genzyme's portfolio including Cerezyme, Fabrazyme, Myozyme, Lumizyme, Thyrogen, Thymoglobulin, Campath, and select pipeline candidates.
Growth in the second quarter was driven by continued growth of Lumizyme in the U.
Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.